Gastro Unit, Medical Division, Hvidovre University Hospital, Hvidovre, Denmark.
First Department of Medicine, Semmelweis University, Budapest, Hungary.
J Crohns Colitis. 2021 Sep 25;15(9):1573-1587. doi: 10.1093/ecco-jcc/jjab029.
New data suggest that incidence and prevalence of inflammatory bowel diseases [IBD] are still increasing worldwide, and approximately 0.2% of the European population suffer from IBD at the present time. Medical therapy and disease management have evolved significantly in recent decades, with an emphasis on tight objective monitoring of disease progression and a treat-to-target approach in Europe and also worldwide, aiming to prevent early bowel damage and disability. Surgery rate declined over time in Europe, with 10-30% of CD and 5-10% of UC patients requiring a surgery within 5 years. The health economic burden associated with IBD is high in Europe. Direct health care costs [approximately €3500 in CD and €2000 in UC per patient per year] have shifted from hospitalisation and surgery towards drug-related expenditures with the increasing use of biologic therapy and other novel agents, and substantial indirect costs arise from work productivity loss [approximately €1900 per patient yearly]. The aim of this paper is to provide an updated review of the burden of IBD in Europe by discussing current data on epidemiology, disease course, risk for surgery, hospitalisation, and mortality and cancer risks, as well as the economic aspects, patient disability, and work impairment, by discussing the latest population-based studies from the region.
新数据表明，炎症性肠病（IBD）的发病率和患病率仍在全球范围内持续上升，目前约有 0.2%的欧洲人口患有 IBD。近几十年来，医学治疗和疾病管理有了显著的发展，重点是对疾病进展进行严格的客观监测，并采用针对目标的治疗方法，在欧洲乃至全球范围内，旨在预防早期肠道损伤和残疾。欧洲的手术率随时间呈下降趋势，在 5 年内，约有 10-30%的 CD 和 5-10%的 UC 患者需要手术。IBD 在欧洲的健康经济负担很高。直接医疗保健费用（每年每位 CD 患者约 3500 欧元，UC 患者约 2000 欧元）已从住院和手术费用转移到与药物相关的支出，随着生物治疗和其他新型药物的使用增加，间接费用也很高，主要来自工作生产力损失（每年每位患者约 1900 欧元）。本文旨在通过讨论该地区最新的基于人群的研究，对欧洲 IBD 的负担进行最新的综述，讨论流行病学、疾病过程、手术风险、住院和死亡率和癌症风险，以及经济方面、患者残疾和工作障碍等方面的当前数据。
